Pan Roubai, Xu Yan, Zong Xiao, Yang Qian, Tudi Xierenayi, Xi Rui, Fan Qin, Tao Rong
Department of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.
Rev Cardiovasc Med. 2023 Nov 16;24(11):316. doi: 10.31083/j.rcm2411316. eCollection 2023 Nov.
Limited research has been conducted to investigate the impact of secondary mitral regurgitation (MR) in heart failure (HF) patients with different levels of estimated pulmonary artery systolic pressure (ePASP).
A total of 468 patients suffering from HF and secondary MR were enrolled and categorized into non-severe and severe MR groups based on the degree of MR. The primary endpoint of the study was a composite of cardiovascular death and a first-heart-failure hospitalization. The secondary endpoints were the primary outcomes, individually. The outcomes of the two groups were compared. Patients were further classified based on whether their ePASP was 50 mmHg or 50 mmHg. Subsequently, the outcomes of the non-severe and severe MR groups were compared within each ePASP category.
In a median (SD) follow-up of 694 (410) days, severe MR was associated with higher risk for primary endpoints in patients with heart failure, especially in those with ePASP 50 mmHg. In patients with ePASP 50 mmHg, the prognostic value of severe MR was diminished.
Assessment of the severity of MR can identify heart failure patients who are at greater risks for poor clinical outcomes. Additionally, the prognostic value of secondary MR was more pronounced in patients with elevated ePASP.
针对不同估计肺动脉收缩压(ePASP)水平的心力衰竭(HF)患者,关于继发性二尖瓣反流(MR)影响的研究有限。
共纳入468例患有HF和继发性MR的患者,并根据MR程度分为非重度和重度MR组。该研究的主要终点是心血管死亡和首次心力衰竭住院的复合终点。次要终点分别为各个主要结局。比较两组的结局。患者还根据其ePASP是否≤50 mmHg或>50 mmHg进一步分类。随后,在每个ePASP类别中比较非重度和重度MR组的结局。
在中位(标准差)694(410)天的随访中,重度MR与心力衰竭患者的主要终点风险较高相关,尤其是在ePASP>50 mmHg的患者中。在ePASP≤50 mmHg的患者中,重度MR的预后价值降低。
评估MR的严重程度可以识别出临床结局较差风险较高的心力衰竭患者。此外,继发性MR的预后价值在ePASP升高的患者中更为明显。